Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

ABCB4 missense mutations D243A, K435T, G535D, I490T, R545C, and S978P significantly impair the lipid floppase and likely predispose to secondary pathologies in the human population.

Andress EJ, Nicolaou M, McGeoghan F, Linton KJ.

Cell Mol Life Sci. 2017 Jul;74(13):2513-2524. doi: 10.1007/s00018-017-2472-6. Epub 2017 Feb 20.

2.

Multilabel immunofluorescence and antigen reprobing on formalin-fixed paraffin-embedded sections: novel applications for precision pathology diagnosis.

Pan J, Thoeni C, Muise A, Yeger H, Cutz E.

Mod Pathol. 2016 Jun;29(6):557-69. doi: 10.1038/modpathol.2016.52. Epub 2016 Mar 4.

3.

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.

Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Påhlman I, Graffner H, Krones E, Fickert P, Wahlström A, Ståhlman M, Paumgartner G, Marschall HU, Trauner M.

J Hepatol. 2016 Mar;64(3):674-81. doi: 10.1016/j.jhep.2015.10.024. Epub 2015 Oct 31.

4.

Sensitization to autoimmune hepatitis in group VIA calcium-independent phospholipase A2-null mice led to duodenal villous atrophy with apoptosis, goblet cell hyperplasia and leaked bile acids.

Jiao L, Gan-Schreier H, Tuma-Kellner S, Stremmel W, Chamulitrat W.

Biochim Biophys Acta. 2015 Aug;1852(8):1646-57. doi: 10.1016/j.bbadis.2015.04.025. Epub 2015 May 7.

5.

Cholestatic liver disease.

Jüngst C, Lammert F.

Dig Dis. 2013;31(1):152-4. doi: 10.1159/000347210. Epub 2013 Jun 17. Review.

PMID:
23797137
6.

The genetics of complex cholestatic disorders.

Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL.

Gastroenterology. 2013 Jun;144(7):1357-74. doi: 10.1053/j.gastro.2013.03.053. Epub 2013 Apr 10. Review.

7.

Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice.

Jahnel J, Fickert P, Langner C, Högenauer C, Silbert D, Gumhold J, Fuchsbichler A, Trauner M.

Liver Int. 2009 Oct;29(9):1316-25. doi: 10.1111/j.1478-3231.2009.02044.x. Epub 2009 Jun 24.

PMID:
19558576
8.

A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.

Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M.

Am J Pathol. 2007 Aug;171(2):525-36. Epub 2007 Jun 28.

9.

Cholestasis and cholestatic syndromes.

Rutherford AE, Pratt DS.

Curr Opin Gastroenterol. 2006 May;22(3):209-14. Review.

PMID:
16550034
10.

Molecular basis of intrahepatic cholestasis.

Carlton VE, Pawlikowska L, Bull LN.

Ann Med. 2004;36(8):606-17. Review.

PMID:
15768832
11.

BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis.

Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, Beuers U, Meier PJ.

Hepatology. 2004 Mar;39(3):779-91.

PMID:
14999697
12.

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Paumgartner G, Beuers U.

Hepatology. 2002 Sep;36(3):525-31. Review.

PMID:
12198643
13.

Regulation of organic anion transporters in a new rat model of acute and chronic cholangitis resembling human primary sclerosing cholangitis.

Geier A, Dietrich CG, Lammert F, Orth T, Mayet WJ, Matern S, Gartung C.

J Hepatol. 2002 Jun;36(6):718-24.

PMID:
12044520

Supplemental Content

Loading ...
Support Center